Catalyst Dossier · compiled by CeliA 🧫
Arrowhead Pharmaceuticals, Inc. (ARWR)
Pharmaceutical Preparations · market cap $11.5B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-02-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Arrowhead Pharmaceuticals (ARWR) is a Pasadena-based RNAi-focused biopharmaceutical company with a broad pipeline spanning cardiovascular, metabolic, hepatic, pulmonary, and neurological disease. Its lead asset, plozasiran, has completed Phase 3 in Familial Chylomicronemia Syndrome (FCS) and severe hypertriglyceridemia, with a Phase 3 readout also recently completed for zodasiran in homozygous familial hypercholesterolemia (HoFH). At ~$84/share ($11.8B market cap), the stock is pricing in significant pipeline optionality despite net debt of $533M and limited near-term revenue clarity.
The catalyst path
- 2027-02-15 (est.)Phase 2 · ARO-ALK7imp 7/10
- 2027-06-15 (est.)Phase 2 · ARO-MAPT-SCimp 7/10
- 2027-08-20 (est.)Phase 3 · zodasiran Injectionimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ARO-DIMERPA | Phase 2 | Hyperlipidemia; Mixed |
| ARO-DM1 Intravenous (IV) Infusion | Phase 2 | Myotonic Dystrophy 1 |
| ARO-CFB | Phase 2 | IgA Nephropathy |
| ARO-MMP7 Inhalation Solution | Phase 2 | Idiopathic Pulmonary Fibrosis |
| Plozasiran | Phase 3 | Familial Chylomicronemia |
| ARO-APOC3 | Phase 2 | Mixed Dyslipidemia |
| ARO-MAPT-SC | Phase 2 | Alzheimer Disease |
| ARO-INHBE | Phase 2 | Obesity |
| ARO-HSD Injection | Phase 2 | Non-alcoholic Steatohepatitis |
| ARO-AAT | Phase 2 | Alpha 1-Antitrypsin Deficiency |
| zodasiran Injection | Phase 3 | Homozygous Familial Hypercholesterolemia |
| ARO-C3 | Phase 2 | C3 Glomerulopathy |
| ARO-ALK7 | Phase 2 | Obesity |
| ARO-HBV | Phase 2 | Hepatitis B |
| Plozasiran Injection | Phase 3 | Severe Hypertriglyceridemia |
| ARO-RAGE | Phase 2 | Asthma |
| Fazisiran Injection | Phase 2 | Alpha 1-Antitrypsin Deficiency |
| ARO-ANG3 | Phase 2 | Mixed Dyslipidemia |
| ARO-ANG 3 Injection | Phase 2 | Homozygous Familial Hypercholesterolemia |
| ARO-DUX4 for Injection | Phase 2 | Facio-Scapulo-Humeral Dystrophy |
Price & technical context
3-month
+15.0%
6-month
+24.1%
12-month
+422.4%
52-wk range
$16.06–$88.70
vs 50-day MA
+8.9%
vs 200-day MA
+31.3%
Realized vol
89.1%
Max drawdown
-65.5%
Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ARWR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.